• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

FDA of­fers guid­ance for gener­ic drug de­vel­op­ers of hy­drox­y­chloro­quine, chloro­quine

6 years ago
FDA+
Coronavirus

Gilead takes a hit af­ter a close­ly-watched Covid-19 tri­al of remde­sivir is qui­et­ly ter­mi­nat­ed, rais­ing fresh doubts

6 years ago
R&D
Coronavirus

Mol­e­cule-in-21-days AI start­up In­sil­i­co adds Boehringer to list of Big Phar­ma part­ners

6 years ago
Deals
AI

Covid-19 roundup: Trump is crit­i­cized for cut­ting off WHO fund­ing; J&J sets up TV show to chron­i­cle vac­cine ...

6 years ago
Coronavirus

LEO Phar­ma mounts an­oth­er chal­lenge to the eczema gi­ants, bet­ting $40M cash on a drug from Chi­na

6 years ago
Deals

One of the best con­nect­ed biotech star­tups in Boston snags a plum dis­cov­ery deal with No­var­tis

6 years ago
Deals

As GSK and Sanofi promise to pro­duce a Covid-19 vac­cine at In­dy 500 speed, some ex­perts start to push back on ...

6 years ago
R&D
Coronavirus

Johns Hop­kins re­searchers pub­lish a how-to guide­book on Covid-19 plas­ma trans­fu­sions

6 years ago
Coronavirus

Al­ny­lam's new pipeline star gets on FDA fast track; ARCH-backed biotech nabs or­phan drug sta­tus

6 years ago
News Briefing

Phar­ma­cyclics bil­lion­aire Bob Dug­gan takes the helm of an­oth­er biotech — and he faces an even big­ger up­hill climb ...

6 years ago
People

Tout­ing new way of min­ing neu­ro tar­gets, Take­da spin­out draws $45M from GV, Bill Gates, Fore­site

6 years ago
Financing

Covid-19 roundup: J&J charts swift path to 1B vac­cine dos­es; Em­bassy ca­ble spot­lights pos­si­ble Wuhan lab con­nec­tion ...

6 years ago
Coronavirus

Mi­cro-cap Mei Phar­ma lands $100M up­front on be­lea­guered PI3K path­way

6 years ago
Deals
R&D

Plough­ing through a crowd­ed PD-(L)1 mar­ket, BeiGene loads up on promis­ing lung can­cer da­ta

6 years ago
R&D
China

Mod­er­na's mis­sion to spear­head a rev­o­lu­tion in vac­cine R&D comes cen­ter stage to­day as the world faces a cru­cial ...

6 years ago
R&D
Coronavirus

FDA re­ports more short­ages of drugs used to put Covid-19 pa­tients on ven­ti­la­tors

6 years ago
FDA+
Coronavirus

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

6 years ago
R&D
Coronavirus

Q&A: An­a­lyst-turned biotech ex­ec-turned an­a­lyst reads the biotech Q1 tea leaves

6 years ago
People
R&D

'Why not do it now?' Al­ny­lam's John Maraganore takes up Black­stone's $2B of­fer to build the fi­nal 'bridge to ...

6 years ago
Deals

Covid-19 roundup: Tri­al of Trump's fa­vorite Covid-19 drug nixed on ear­ly death risk; Is An­tho­ny Fau­ci on thin ice ...

6 years ago
Coronavirus

How you can help us grow End­points News through the pan­dem­ic

6 years ago
Publisher's note

As­traZeneca stops lung can­cer tri­al ear­ly, af­ter star drug Tagris­so in­duces 'over­whelm­ing' ef­fi­ca­cy

6 years ago
R&D

Judge slaps en­hanced dam­ages on Gilead/Kite for ‘will­ful’ patent vi­o­la­tion, boost­ing award to a block­buster $1.2B ...

6 years ago
R&D

As­traZeneca, Mer­ck win quick OK for a rare dis­ease drug — as the FDA de­clares it can still move fast dur­ing a ...

6 years ago
Pharma
FDA+
First page Previous page 836837838839840841842 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times